Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.00309-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Chunfu Wang und 17 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Biology, ViiV Healthcare, Branford, Connecticut, USA. Hauptthemen laut MEDLINE: HIV-1, Anti-HIV Agents, Capsid Proteins, Capsid. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
With its high degree of conservation and critical role in multiple steps of the HIV-1 life cycle, the HIV-1 capsid protein presents an attractive therapeutic target. Herein, the virologic properties of the HIV-1 capsid inhibitors VH4004280 (VH-280) and VH4011499 (VH-499), including potency, mechanisms of action, and resistance profiles, are described. VH-280 and VH-499 inhibited panels of HIV-1 laboratory strains and viruses containing capsid sequences from clinical isolates with half-maximal effective concentrations in the picomolar range. Time-of-addition experiments determined that the primary block to HIV-1 replication occurred after nuclear import and before integration; however, measurements of replication intermediates by quantitative polymerase chain reaction, Gag degradation, p24 release, and virion morphology by cryo-electron microscopy indicate that VH-280 and VH-499 also block nuclear import, total reverse transcript production, integration, virion assembly, and maturation. In vitro resistance selection identified Q67H, A105E, T107D/N, and combinations of these substitutions as conferring 6- to >5,000-fold reductions in susceptibility to both compounds. Certain resistance-associated mutations selected by other capsid inhibitors also reduced susceptibility. Overall, the preclinical virology profiles and other drug-like properties support the potential of VH-280 and VH-499 as long-acting agents for HIV-1 treatment and prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Discovery Biology, ViiV Healthcare, Branford, Connecticut, USA.
- Discovery Chemistry, ViiV Healthcare, Branford, Connecticut, USA.
- Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA.
ORCID-Profile: Chunfu Wang, Mark Krystal
Förderung
- ViiV Healthcare
Zitieren
APA
Wang, C., Huang, H., Valera, L., Parcella, K., Iwuagwu, C., McAuliffe, B., Falk, P. J., O'Boyle Ii, D. R., Rose, R. E., Padilla, R. R., Wu, C., Xiong, Y., Kadow, J., Hanumegowda, U., Sardo, L., Gillis, E. P., Krystal, M., & Fridell, R. A. (2025). Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00309-25
Vancouver
Wang C, Huang H, Valera L, Parcella K, Iwuagwu C, McAuliffe B, et al. Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00309-25
BibTeX
@article{Wang2025,
author = {Wang, Chunfu and Huang, Haichang and Valera, Lourdes and Parcella, Kyle and Iwuagwu, Christiana and McAuliffe, Brian and Falk, Paul J and O'Boyle Ii, Donald R and Rose, Ronald E and Padilla, Ricardo Ramírez and Wu, Chunxiang and Xiong, Yong and Kadow, John and Hanumegowda, Umesh and Sardo, Luca and Gillis, Eric P and Krystal, Mark and Fridell, Robert A},
title = {Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.00309-25}
}
EUVIMED